Articles tagged with Antiinflammatory Drugs
Patients with asthma often view their condition as a temporary health problem, leading to inadequate treatment and poor disease control. A study found that nearly half of hospitalised asthma patients believed they only had asthma when symptoms appeared.
Researchers argue that COX-2 inhibitors, including Vioxx, are as effective as traditional NSAIDs but carry fewer gastric side effects. They suggest these drugs may be the best option for some patients without cardiovascular risk factors who cannot tolerate traditional NSAIDs.
A promising new therapy has been approved by the FDA for patients with moderate to severe ulcerative colitis, offering improved lives through reduced inflammation and increased mobility. Nearly 70% of patients experienced clinical response and remission within a year of treatment.
A study of 4,975 patients found that short-term NSAID use does not increase the risk of heart attack. Long-term NSAID use, particularly for over a year, may slightly raise this risk. The findings also suggest individual NSAIDs have varying cardiovascular effects.
Researchers have confirmed that methotrexate and leflunomide are safe and effective treatments for children with severe juvenile rheumatoid arthritis. The study found a higher response rate in children compared to adults, providing new hope for families affected by this chronic disease.
A non-surgical method called mesotherapy claims to remove fat and contour the body, but there is no scientific evidence supporting its safety or efficacy. Plastic surgeons recommend liposuction instead due to its proven track record of safely removing fat.
A study found that adult patients with mild persistent asthma fare similarly whether they take inhaled steroids daily or only during symptoms. This suggests a possible cost-saving benefit, as estimated annual medication costs would be $2 billion lower if patients took steroids only when needed.
Researchers developed patient scenarios to compare costs of three therapies for treating chronic arthritis pain. The study found that combining a non-steroidal anti-inflammatory drug with an acid-reducing drug was less expensive, safer, and more effective than using a Cox-2 inhibitor alone.
A study found celecoxib safe for short-term use in patients with cirrhosis, whereas naproxen harms renal function. Celecoxib did not affect kidney function, while naproxen reduced glomerular filtration rate and increased serum creatinine levels.
A meta-analysis of 19 randomized trials found COX-2 inhibitors significantly associated with blood pressure elevation compared to NSAIDs and placebos. This increased risk may be clinically significant for patients at elevated cardiovascular risk, particularly in the elderly population.
Researchers have developed an efficient new strategy to synthesize a natural marine product with promising anti-tuberculosis activity, overcoming challenges of conventional chemistry. The breakthrough enables the production of gram quantities in just days, paving the way for developing potential anti-inflammatory and anticancer agents.
Researchers analyzed data from the National Center for Health Statistics to show that COX-2 inhibitors were frequently prescribed to patients at low risk of gastrointestinal side effects. The study found a rapid nationwide shift away from older, inexpensive drugs with better established safety and efficacy.
Researchers at Columbia University have identified indoprofen as a potential therapeutic candidate for spinal muscular atrophy (SMA), a neurodegenerative disease affecting thousands of children worldwide. The discovery was made using a high-throughput chemical genetics approach and involves the use of a novel analysis tool called SLIMS.
A new study published in Gastroenterology found that generic anti-inflammatory drug etodolac reduces rates of gastrointestinal complication by more than 60% compared to naproxen, resulting in fewer hospitalizations and cost savings. This significant finding has led the Pharmacy Benefits Management Strategic Healthcare Group for the Vet...
A topical diclofenac sodium solution has been shown to effectively treat symptoms of primary OA of the knee, improving pain and physical function by 45.7% and 36.7%, respectively. The study found that this treatment had a superior efficacy compared to a control solution, with minimal adverse effects related to skin reactions.
Research published in Journal of Applied Ecology reveals that less than 1% of contaminated carcasses can cause rapid declines in vulture populations. Diclofenac poisoning is identified as the main cause of these declines, which are among the most rapid ever recorded for any wild bird species.
Researchers at Ohio State University developed a new anti-cancer agent, OSU-03012, which inhibits Akt and induces programmed cell death in cancer cells. The agent has shown potent activity against various types of cancer, including leukemia and breast and lung cancers.
Patients with knee osteoarthritis prioritize treatment characteristics, such as risk of common adverse side effects and cost, when choosing medication. Non-selective NSAIDs are the least preferred option due to their limited impact on patient preferences.
A study by Yale University researchers found that patients with knee arthritis prefer safer treatment options despite potential reduced efficacy. Older patients rarely opt for anti-inflammatory drugs, indicating the importance of considering individual preferences in treatment decisions.
Researchers discovered Stat3 regulates the inflammatory response in lung tissue, preventing excessive activation and tissue damage. The study suggests enhancing Stat3 activity could lead to new therapeutic drugs for immune-related diseases like COPD.
Researchers found that over half of COX-2 patients take aspirin, leading to a loss of GI protective effects and increased risk of bleeding. Patients should consider alternative NSAIDs or proton pump inhibitors for added protection.
A recent study has found that COX-2 inhibitors may have a lower risk of congestive heart failure compared to non-selective NSAIDs. COX-2 inhibitors rofecoxib and celecoxib showed significantly different risks of hospital admission for heart failure, with users of celecoxib having the same rate as those who had never used NSAIDs.
Researchers found that the rate of total brain volume loss can predict which mildly cognitively impaired individuals are at high risk of developing dementia. Combining this with hippocampus volume measurements provides a strong model for predicting cognitive outcomes.
A study confirmed that alcohol intake is associated with an increased risk of gout, with beer and liquor showing a stronger link than moderate wine consumption. The Health Professionals Follow-up Study found that men who consumed more than 50 grams of alcohol daily had a 2.5 times higher risk of developing gout.
A study clarifies the impact of diet on the risk of gout, revealing that meat and seafood consumption significantly increases risk, while dairy products may be protective. The study's findings suggest a potential benefit to reducing red meat consumption and increasing low-fat dairy intake.
Researchers at Express Scripts found that COX-2 prescribing physicians often co-prescribe gastroprotective drugs, contradicting expert estimates. This challenges the use of expert opinion in estimating practice pattern model inputs and warrants re-evaluation of COX-2 cost-effectiveness models.
Researchers found that meclofenamic acid and flurbiprofen, a currently clinical-trialled drug for prostate and colon cancer, effectively decreased Abeta42 levels by targeting gamma-secretase. This provides promising avenues for Alzheimer's treatment and furthers understanding of how NSAIDs impact AD.
Regular NSAID use for five to nine years reduces breast cancer risk by 21%, while ten-year use increases the reduction to 28%. The study enrolled 80,741 post-menopausal women with no reported history of cancer, other than non-melanoma skin cancer.
According to Dr. Robert Kaniecki, a University of Pittsburgh neurologist, migraine headaches are often underdiagnosed, with over 50% of patients being mislabeled as having 'sinus headache' or 'tension headache'. This can lead to excessive prescriptions for antibiotics and decongestants, contributing to antibiotic resistance.
Researchers found that COX-2 inhibitors impede new bone growth, delaying healing of fractures or joint implants. A six-week 'time-out' period from COX-2 inhibitors is recommended to promote bone recovery.
The study found that COX-2 inhibitors led to a substantial increase in NSAID prescriptions and expenditures among elderly patients in Ontario. The listing of these medications had an immediate impact, accounting for 48% of prescriptions and 66% of expenditures for NSAIDs.
Researchers found that anti-inflammatory agents are more effective in patients at higher risk of death from sepsis. Spiral computed tomography (CT) scans can help identify up to four times more lung cancers than chest x-rays, with 70% of tumors still in Stage 1.
Researchers found no statistical difference between sulindac and placebo groups in preventing polyp development or colon cancer, contradicting previous evidence. Sulindac may be ineffective at preventing polyps in newly diagnosed FAP patients, suggesting a need for alternative treatments.
Research suggests that PGE2 can alleviate intestinal inflammation by inhibiting NF-\u00b8B and JAK/STAT pathways. Additionally, the study highlights the importance of targeting PGE2 receptors in the treatment of inflammatory bowel disease.
Researchers found that nicotine withdrawal causes inflammation and similar biochemical responses as acute or chronic illnesses, potentially leading to depression, fatigue, muscle aches, and appetite changes. Anti-inflammatory treatments may alleviate these symptoms, increasing the likelihood of successful quitting.
A Phase 2 double-blind, placebo-controlled study found that 40 patients with ankylosing spondylitis achieved a significant clinical response when treated with ENBREL (etanercept), with 80% of patients showing improvement in outcome measures. The treatment was generally well-tolerated with no serious adverse events or withdrawals.
Research reveals that selected NSAIDs decrease AB42 levels by up to 80%, providing hope for plaque-reducing drugs without anti-inflammatory side effects. The study suggests a new mechanism through which NSAIDs may confer protection against Alzheimer's disease, independent of direct anti-inflammatory properties.
Researchers at the Gladstone Institute have discovered a new pathway that regulates the activity of NF-kB, a protein controlling key inflammatory and immune responses. The study reveals how acetylation and deacetylation control NF-kB's ability to trigger biological processes.
A study published in JAMA found that patients taking Celebrex had two- to threefold fewer serious gastrointestinal complications compared to those receiving ibuprofen or diclofenac. The medication was also associated with lower incidence of stomach upset, abdominal pain, and nausea.
Free-radical activity was found to be roughly doubled in the frontal and temporal lobes of brains of people who died of Alzheimer's disease. The levels of two biochemical markers of free-radical tissue damage were also elevated in these areas, which are critical for memory and intellectual function.
The new report updates asthma clinical practice guidelines with a focus on early use of anti-inflammatory medication, personalized treatment approaches, and reduced exposure to environmental allergens. The guidelines also include practical tools for physicians and expanded information about identifying specific allergens for each patient.